Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy

Figures & data

Table 1. Participant characteristics

	All subjects (n = 30)
Male (%)	85%
Age (years, median)	38
BMI (kg/m^2, median)	28.1
CD4 + cell count (mm^3, median)	323
HIV RNA(c/ml, median)	29 245

Table 2. Changes from baseline in body composition and bone density

	Week 0 (n = 30)	Week 56 (n = 30)	Week 104 (n = 26)	P-value for ANOVA	Change from baseline to week 56	P-value for pair wise comparison	Change from baseline to week 104	P-value for pair wise comparison
Subcutaneous fat
Limb fat (kg)	9.4 ± 5.4	10.7 ± 5.7	10.3 ± 5.7	0.003	1.3 ± 2.4	0.005	1.2 ± 19	0.004
Limb fat (%)	23.19 ± 10.7	24.51 ± 10.3	23.62 ± 10.2	0.037	1.3 ± 4.0	0.082	1.51 ± 3.4	0.032
Subcutaneous adipose tissue (SAT) (cm^2)	262.61 ± 164.8	283.45 ± 159.29	297.1 ± 176.15	0.014	28.20 ± 74 2	0.059	39.76 ± 59.36	0.003
Truncal fat
Trunk fat (kg)	9.83.5.8	11.64-6.3	11.47 ± 6.8	0.010	1.81 ± 3.6	0.01	1.73 ± 2.6	0.002
Trunk fat (%)	23.38 ± 10.1	25.38 ± 9.8	25.09 ± 10.8	0.011	2.25 ± 4.4	0.009	2.47 ± 4.59	0.011
Visceral adipose tissue (VAT) (cm^2)	78.76 ± 54.96	95.45 ± 69.58	96.26 ± 67.57	0.018	16.70 ± 35.62	0.022	17.26 ± 24.68	0.002
Overall
Total fat (kg)	20.22 ± 10.99	23.39 ± 11.79	22.74 ± 12.26	0.001	3.17 ± 5.93	0.007	2.93 ± 4.41	0.002
Total fat (%)	22.92 ± 9.54	24.63 ± 9.25	24.08 ± 9.64	0.015	1.71 ± 3.73	0.018	1.89 ± 3.66	0.014
VAT/(VAT ± 5AT)	24.68 ± 1058	24.40 ± 10.94	25.72 ± 9.26	0993	NA	NA	NA	NA
Bone mineral density (BMD) (g/cm^4)	1.30 ± 0.13	1.29 ± 013	1.28 ± 013	0.009	0.01 ± 0.03	0.021	0.01 ± 0.03	0.005

Figure 1. Changes in limb and trunk fat

Figure 2. Bone mineral density (BMD) from baseline through week 104.

Table 3. Changes in fasting lipids and insulin resistance

	Week 0 (n = 29)	Week 56 (n = 29)	Week 104 (n = 29)	P-value for ANOVA	Change from baseline to week 56	P-value for pair wise comparison	Change from baseline to week 104	P-value for pair wise comparison
Non-HDL cholesterol	123.9 ± 31.3	126.4 ± 33.7	131.5 ± 33.4	0.21	2.5 ± 22.3	0.54	7.6 ± 26.9	0.14
Triglycerides	100.6 ± 72.5	92.3 ± 53.0	107.7 ± 80.4	0.26	8.3 ± 49.1	0.39	7.1 ± 42.1	0.39
Homeostasis model of assessment-insulin resistance (HOMA-IR)	2.6 ± 2.2	2.7 ± 1.9	2.3 ± 1.7	0.14	0.13 ± 1.8	0.72	0.30 ± 2.2	0.50